Sign in
CompletedNo phase

Compare the Safety and Effectiveness of Two Different Kinds of Stent System in Intracranial Aneurysms

Key facts

Who runs it
Sinomed Neurovita Technology Inc.
Where
China14 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
203 people enrolled
Started
17 Jan 2024
Ended
20 Nov 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • SINOMED IAS Stent System
  • Neuroform Atlas Stent System
Record updated
13 July 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age 18 years to 80 years
  • Wide-necked (Wide-necked is defined as width ≥ 4 mm or a dome-to-neck ratio < 2), saccular, intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.5 mm and ≤ 5mm
  • Modified Rankin Scale (mRS) ≤ 2
  • Subject understands the nature of the procedure, provides voluntary written informed consent prior to the treatment, and is willing to comply with specified follow-up evaluation
  • The investigators judged the use of stent-assisted coil embolization to be appropriate for the treatment of intracranial aneurysm

Who cannot take part

  • Target aneurysm that has been previously treated with vascular embolization or surgery
  • Hospitalized surgical treatment within 30 days before operation, or planned hospitalized surgical treatment within 6 months after surgery
  • Currently enrolled in another investigational device or drug study
  • Target aneurysms are fusiform aneurysms, dissecting aneurysms, pseudoaneurysms, blood blister-like aneurysms, infected aneurysms, aneurysms associated with arteriovenous malformations
  • Subject who had Moyamoya disease, arteriovenous malformations, arteriovenous fistulae, intracranial tumors, or intracranial mass lated to target aneurysms
  • Known hypersensitivity/allergies or contraindication to contrast media, stent components, antiplatelets, anticoagulants
  • Platelet count <50*103/mm3 (50*109/L) or any known coagulation deficiency, or International normalized ratio (INR)>3.0
  • Target aneurysm is an aneurysm requiring staged procedure
  • Acutely ruptured aneurysm within 14 days of enrollment
  • Hunt and Hess (H\&H) scale ≥3
  • Severe stenosis or tortuosity of intracranial arteries or anatomical anomalies that make it difficult to reach the site of the lesion with device
  • Life expectancy < 1 year, and unable to complete the required follow-ups
  • Female who was pregnant or breastfeeding, women/men planning to havve children in the next year

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of this trial is to evaluate the safety and efficacy of SINOMED IAS in patients with intracranial aneurysms.

The 2 groups in the trial

  • SINOMED IAS Stent SystemTreatment being tested

    The SINOMED IAS Stent System is intended for use with occlusive devices in the treatment of intracranial aneurysms.

  • Neuroform Atlas Stent SystemExisting treatment, for comparison

    The Neuroform Atlas Stent System is intended for use with occlusive devices in the treatment of intracranial aneurysms.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the SINOMED IAS for the Treatment of Intracranial Aneurysms
Record updated
13 July 2026